Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Essential Thrombocythemia (ET) Clinical Trial

Official title:
A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Status Completed

Clinical Trial Summary

The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01467661
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	October 27, 2010
Completion date	May 1, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01198717` - Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Completed	`NCT01214915` - Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia	Phase 3
Active, not recruiting	`NCT02577926` - The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Phase 2
Completed	`NCT03625895` - Agrylin Drug Use-Result Survey
Completed	`NCT01816256` - Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms	N/A
Completed	`NCT01352585` - Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Completed	`NCT04243122` - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients	Phase 2